Keyphrases
Multiple Sclerosis
100%
Systematic Literature Review
100%
Pharmacological Treatment
100%
Ocular Side Effects
100%
Treatment-related Adverse Events
100%
Ocular Treatment
100%
Inclusion Criteria
66%
Interferon-α (IFN-α)
66%
Quality Tools
66%
Text Reading
66%
Siponimod
66%
Amantadine
66%
Fingolimod
66%
Alemtuzumab
66%
Latin America (LATAM)
33%
Prospero
33%
Systematic Meta-analysis
33%
Meta-analysis
33%
Africa
33%
Life-threatening
33%
Evidence-based Recommendations
33%
Embase
33%
Acute Retinal Necrosis
33%
Reporting Item
33%
Retinopathy
33%
Macular Edema
33%
MEDLINE
33%
Rituximab
33%
Search Strategy
33%
Selection Criteria
33%
Methodological Assessment
33%
Opportunistic Infections
33%
Teriflunomide
33%
Narrative Synthesis
33%
Corneal Edema
33%
Thyroid Eye Disease
33%
Joanna Briggs Institute
33%
Multiple Sclerosis Treatment
33%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
33%
Ocular Symptoms
33%
Hyperbaric Oxygen
33%
Natalizumab
33%
Estriol
33%
Therapy-related
33%
Medicine and Dentistry
Systematic Review
100%
Adverse Event
100%
Multiple Sclerosis
100%
Drug Therapy
100%
Interferon
50%
Alemtuzumab
50%
Amantadine
50%
Fingolimod
50%
Siponimod
50%
Immunoglobulin
25%
Narrative
25%
Meta-Analysis
25%
Endocrine Ophthalmopathy
25%
Macular Edema
25%
Retinopathy
25%
Opportunistic Infection
25%
Rituximab
25%
Cornea Edema
25%
Teriflunomide
25%
Imilecleucel T
25%
CTLA-4
25%
Acute Retinal Necrosis
25%
Hyperbaric Medicine
25%
Estriol
25%
Natalizumab
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Multiple Sclerosis
100%
Interferon
50%
Amantadine
50%
Alemtuzumab
50%
Fingolimod
50%
Siponimod
50%
Immunoglobulin
25%
Endocrine Ophthalmopathy
25%
Opportunistic Infection
25%
Teriflunomide
25%
Cytotoxic T Lymphocyte Antigen 4
25%
Rituximab
25%
Retinopathy
25%
Macular Edema
25%
Estriol
25%
Imilecleucel T
25%
Natalizumab
25%
Cornea Edema
25%
Necrosis
25%
Neuroscience
Multiple Sclerosis
100%
Drug Therapy
100%
Interferon
50%
Alemtuzumab
50%
Amantadine
50%
Fingolimod
50%
Meta-Analysis
25%
Longitudinal Study
25%
Intravenous Immunoglobulin
25%
Necrosis
25%
Retinal Disease
25%
Teriflunomide
25%
Thyroid Eye Disease
25%
Cytotoxic T Lymphocyte Antigen 4
25%
Estriol
25%
Natalizumab
25%
Rituximab
25%
Hyperbaric Medicine
25%